Asia

Singapore develops its first cancer drug

Thursday, March 17, 2011 01:27 PM

Singapore has developed its first cancer drug, SB-939, from two Singapore-based cancer institutes and a biotechnology company, S*BIO, according to Channel News Asia.   The Singapore National University Cancer Institute, the Cancer Institute of Singapore and S*BIO have collaborated for the phase I trials.

More... »

CRO QPS acquires Qualitix

Wednesday, March 9, 2011 01:28 PM

QPS, a global GLP/GCP-compliant CRO providing testing services for preclinical and clinical R&D, has acquired a majority interest of Qualitix Clinical Research. Qualitix, a spin-off of Taiwan-based biotech Genovate, is a CRO and site management organization (SMO) with offices in Taiwan and China. Genovate will retain a minority interest in Qualitix, which will be known as QPS-Qualitix Taiwan.

More... »

Eisai reports new data on Halaven

Tuesday, March 8, 2011 10:24 AM

Eisai, based in Japan, reported new data confirming its marine-derived drug Halaven improves overall survival in women with late-stage breast cancer. 

More... »

WuXi reports 2Q revenue growth after Charles River deal fails

Friday, August 6, 2010 08:45 AM

Shanghai-based WuXi PharmaTech will receive a breakup fee of $30 million from Charles River Laboratories International, whose previously announced purchase of Wuxi was terminated by mutual agreement due to Charles River shareholder opposition.

More... »

PPD Named Best CRO in Asia

Thursday, July 1, 2010 08:20 AM

PPD was named Best Contract Research Organization (CRO) in Asia at the World Vaccine Congress’ inaugural 2010 Vaccine Industry Excellence (ViE) Asia Awards held in Singapore.

More... »

Parexel Adds Two Locations in China

Thursday, May 27, 2010 09:11 AM

Parexel has opened two new offices in China, increasing its presence in the Asia-Pacific region to 17 locations, in order to meet growing demand for clinical development and regulatory consulting services from drug sponsors looking for more opportunities to include China in global drug development strategies.

More... »

BBK Worldwide Partners with CROee in Japan

Monday, May 24, 2010 09:09 AM

BBK Worldwide (BBK), a patient recruitment company, signed a strategic alliance with CROèe, a Japanese CRO specializing in enrollment management.

More... »

WuXi Reports 36% Revenue Growth, Prepares for Sale to Charles River

Wednesday, May 12, 2010 07:07 AM

Chinese contract research organization WuXi Pharmatech reported 36% revenue growth in what may be one of the company’s last quarterly earnings statements if an acquisition by Charles River Laboratories goes through.

More... »

Charles River Labs to Acquire WuXi PharmaTech for $1.6B

Monday, April 26, 2010 08:32 AM

Preclinical contract research organization (CRO) Charles River Laboratories announced this morning plans to acquire Chinese CRO Wuxi PharmaTech in a deal valued at $1.6 billion.

More... »

WuXi Partners with Janssen to Meet GLP Standards in China Lab

Thursday, March 4, 2010 06:10 AM

Chinese CRO WuXi PharmaTech expanded its strategic collaboration with Johnson & Johnson Pharmaceutical Research and Development(a division of Janssen Pharmaceutica) to provide preclinical services to Janssen and to eventually offer Good Laboratory Practice (GLP) toxicology services at WuXi’s facility in Suzhou, China.

More... »